{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:22:52Z","timestamp":1787768572894,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>\n                    Luteolin exhibited antibacterial activity against\n                    <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                    and its chemical structure similar to that of ciprofloxacin (CPF) which works by inhibiting DNA gyrase\n                    <jats:italic toggle=\"yes\"\/>\n                    . Filtrate from passion fruit extract containing luteolin and its derivatives could inhibit extended-spectrum \u03b2-lactamase (ESBL)-producing\n                    <jats:italic toggle=\"yes\">E<\/jats:italic>\n                    .\n                    <jats:italic toggle=\"yes\">coli<\/jats:italic>\n                    . Antibacterial compounds that can also inhibit ESBL will be valuable compounds to overcome the problem of resistant bacteria. This study aimed to ensure the potency of luteolin and luteolin derivatives targeting DNA gyrase and ESBL by\n                    <jats:italic toggle=\"yes\">in silico<\/jats:italic>\n                    approach. Docking simulation of ligands L1-L14 was performed using AutoDock Vina, and pharmacokinetics and toxicity (absorption, distribution, metabolism, excretion, and toxicity) profiles were predicted by pKCSM online. The docking result revealed higher binding affinity on DNA gyrase (PDB.1KZN) of 12 luteolin derivatives (energy &lt;\u22127.6 kcal\/mol) compared to CPF and higher affinity (energy &lt;\u22126.27 kcal\/mol) of all compounds than clavulanic acid against ESBL CTX-M-15 (PDB.4HBU). The compounds could be absorbed through the human intestine moderately, which showed low permeability to blood\u2013brain barrier, nontoxic and nonhepatotoxic. The most active luteolin glycoside (L6) is capable to inhibit DNA gyrase and ESBL from\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    which provided the potential against resistant bacteria and was promoted as lead compounds to be developed further.\n                  <\/jats:p>","DOI":"10.4103\/japtr.japtr_217_23","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T03:00:17Z","timestamp":1705546817000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["In silico analysis of luteolin derivatives as antibacterial agents targeting DNA gyrase and CTX-M-15 extended-spectrum \u03b2-lactamase of Escherichia coli"],"prefix":"10.4103","volume":"15","author":[{"given":"Nuzul Wahyuning","family":"Diyah","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwi Ayu","family":"Indriani","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachma","family":"Dessidianti","sequence":"additional","affiliation":[{"name":"Study Program of Pharmacy, Faculty of Health Science, Universitas Muhammadiyah Surabaya, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siswandono","family":"Siswandono","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"R1-20240903","doi-asserted-by":"crossref","first-page":"61","DOI":"10.30699\/ijp.14.1.61","article-title":"Bacteria producing extended spectrum \u03b2-lactamases (ESBLs) in hospitalized patients: Prevalence, antimicrobial resistance pattern and its main determinants","volume":"14","author":"Yousefipour","year":"2019","journal-title":"Iran J Pathol"},{"key":"R2-20240903","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.mimet.2019.03.019","article-title":"Detection of extended-spectrum \u03b2-lactamase (ESBL)-producing Enterobacteriaceae using the MALDI biotyper selective testing of antibiotic resistance-\u03b2-lactamase (MBT STAR-BL) assay","volume":"160","author":"Kawamoto","year":"2019","journal-title":"J Microbiol Methods"},{"key":"R3-20240903","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/1040841X.2012.691460","article-title":"Epidemiology and genetics of CTX-M extended-spectrum \u03b2-lactamases in Gram-negative bacteria","volume":"39","author":"Zhao","year":"2013","journal-title":"Crit Rev Microbiol"},{"key":"R4-20240903","first-page":"163","article-title":"Antibiotik Golongan Fluorokuinolon: Manfaat Dan Kerugian (Fluoroquinolones Antibiotics: Benefit and Side Effects)","volume":"26","author":"Raini","year":"2016","journal-title":"Media Litbangkes"},{"key":"R5-20240903","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1074\/jbc.M115.689554","article-title":"DNA gyrase is the target for the quinolone drug ciprofloxacin in Arabidopsis thaliana","volume":"291","author":"Evans-Roberts","year":"2016","journal-title":"J Biol Chem"},{"key":"R6-20240903","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1080\/14756366.2022.2084088","article-title":"Discovery of N-quinazolinone-4-hydroxy-2-quinolone-3-carboxamides as DNA gyrase B-targeted antibacterial agents","volume":"37","author":"Xue","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"key":"R7-20240903","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1021\/acs.jmedchem.9b01279","article-title":"\u03b2-lactamase inhibitors to restore the efficacy of antibiotics against superbugs","volume":"63","author":"Gonz\u00e1lez-Bello","year":"2020","journal-title":"J Med Chem"},{"key":"R8-20240903","doi-asserted-by":"crossref","first-page":"10471","DOI":"10.1038\/s41598-021-90035-7","article-title":"Antibacterial activity and mechanism of plant flavonoids to gram-positive bacteria predicted from their lipophilicities","volume":"11","author":"Yuan","year":"2021","journal-title":"Sci Rep"},{"key":"R9-20240903","first-page":"1","article-title":"Antibacterial Activity of Apigenin, Luteolin, and their C-Glucosides","author":"Karpi\u0144ski","year":"2019","journal-title":"Proceedings of the 5th International Electronic Conference on Medicinal Chemistry"},{"key":"R10-20240903","doi-asserted-by":"crossref","first-page":"22","DOI":"10.23869\/bphjbr.26.1.20204","article-title":"Inhibitory activity of fermentation filtrate of red passion fruit pulp (Passiflora edulis sims.) against Escherichia coli extended-spectrum beta-lactamase (ESBL) and methicillin resistant Staphylococcus aureus (MRSA)","volume":"26","author":"Nurrosyidah","year":"2020","journal-title":"J Biol Res"},{"key":"R11-20240903","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.foodchem.2012.07.101","article-title":"C-dideoxyhexosyl flavones from the stems and leaves of Passiflora edulis sims","volume":"136","author":"Xu","year":"2013","journal-title":"Food Chem"},{"key":"R12-20240903","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s12649-018-0269-y","article-title":"E\ufb00ect of extraction process on composition, antioxidant and antibacterial activity of oil from yellow passion fruit (Passi\ufb02ora edulis var. Flavicarpa) seeds","volume":"10","author":"Pereira","year":"2019","journal-title":"Waste Biomass Valorization"},{"key":"R13-20240903","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jphotobiol.2012.10.006","article-title":"Synergistic activity of luteolin and amoxicillin combination against amoxicillin-resistant Escherichia coli and mode of action","volume":"117","author":"Eumkeb","year":"2012","journal-title":"J Photochem Photobiol B"},{"key":"R14-20240903","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.3390\/ijms20184331","article-title":"Molecular docking: Shifting paradigms in drug discovery","volume":"20","author":"Pinzi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R15-20240903","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1515\/jbcpp-2020-0455","article-title":"Design of gossypetin derivatives based on naturally occurring flavonoid in Hibiscus sabdariffa and the molecular docking as antibacterial agents","volume":"32","author":"Diyah","year":"2021","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"R16-20240903","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jbiotec.2018.05.005","article-title":"Class A \u03b2-lactamases and inhibitors: In silico analysis of the binding mode and the relationship with resistance","volume":"279","author":"Pereira","year":"2018","journal-title":"J Biotechnol"},{"key":"R17-20240903","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fphar.2020.00617","article-title":"Passiflora edulis: An insight into current researches on phytochemistry and pharmacology","volume":"11","author":"He","year":"2020","journal-title":"Front Pharmacol"},{"key":"R18-20240903","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5604\/17331331.1204473","article-title":"Microbial glycosylation of flavonoids","volume":"65","author":"Sordon","year":"2016","journal-title":"Pol J Microbiol"},{"key":"R19-20240903","first-page":"258","article-title":"Molecular descriptor based on a molar refractivity partition using Randic-type graph-theoretical invariant","volume":"5","author":"Padr\u00f3n","year":"2002","journal-title":"J Pharm Pharm Sci"},{"key":"R20-20240903","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/092986709787002817","article-title":"Topological polar surface area: A useful descriptor in 2D-QSAR","volume":"16","author":"Prasanna","year":"2009","journal-title":"Curr Med Chem"},{"key":"R21-20240903","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/1177391X0700100003","article-title":"The pK (a) distribution of drugs: Application to drug discovery","volume":"1","author":"Manallack","year":"2007","journal-title":"Perspect Medicin Chem"},{"key":"R22-20240903","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4155\/fmc.13.61","article-title":"Ask the experts: Past, present and future of the rule of five","volume":"5","author":"Baell","year":"2013","journal-title":"Future Med Chem"},{"key":"R23-20240903","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tim.2007.03.004","article-title":"Engineering the glycosylation of natural products in actinomycetes","volume":"15","author":"Salas","year":"2007","journal-title":"Trends Microbiol"},{"key":"R24-20240903","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J Med Chem"},{"key":"R25-20240903","first-page":"53","article-title":"Biopharmaceutics and Applied Pharmacokinetics","author":"Shargel","year":"2005"},{"key":"R26-20240903","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1124\/jpet.113.203257","article-title":"Substrate-dependent ligand inhibition of the human organic cation transporter OCT2","volume":"346","author":"Belzer","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"R27-20240903","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/jop.2021.0069","article-title":"Eyes on Lipinski's rule of five: A New \u201crule of thumb\u201d for physicochemical design space of ophthalmic drugs","volume":"38","author":"Karami","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"key":"R28-20240903","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.addr.2016.05.007","article-title":"BDDCS, the rule of 5 and drugability","volume":"101","author":"Benet","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"R29-20240903","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/17460441.2017.1264385","article-title":"Drug discovery beyond the rule of 5 \u2013 Opportunities and challenges","volume":"12","author":"Doak","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"R30-20240903","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11306-014-0733-z","article-title":"A \u2018rule of 0.5\u2019 for the metabolite-likeness of approved pharmaceutical drugs","volume":"11","author":"Hagan","year":"2015","journal-title":"Metabolomics"}],"container-title":["Journal of Advanced Pharmaceutical Technology &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/JAPTR.JAPTR_217_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:15:04Z","timestamp":1787768104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/JAPTR.JAPTR_217_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/japtr.japtr_217_23","relation":{},"ISSN":["2231-4040","0976-2094"],"issn-type":[{"value":"2231-4040","type":"print"},{"value":"0976-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-04-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}